Inventiva shares take a breather but remain 20% up over one month
The Burgundy-based biotech specializing in fibrotic and metabolic diseases eases off at midday, in a stable Paris market. This pullback follows a rebound sequence that began in the autumn, which brought the stock back above its short-term averages.
A 1.5% decline that leaves the stock well above its short-term averages
Inventiva shares fell 1.53% to €3.53, while the SBF 120 was flat, placing the stock among the largest decliners in the index. The decline is modest in light of the recent rebound: the stock is still up 20.07% over one month and 5.06% over the week.
The stock remains well above its MA20 at €3.29 (a gap of +7.29%) and its MA50 at €3.20 (+10.31%), while the MA200 at €4.06 is still 13.05% above the price.
Resistance at €3.59 is very close, and the stock already broke through the €3.55 level the previous day. Inventiva is listed in Paris (ordinary share, PEA-eligible) and on the Nasdaq (ADS, 1 ADS for 1 share), two lines arbitrated at the same price.
Cash position strengthened in spring, but no revenue in the first half
When publishing its H1 2026 results (on July 29, 2026), the company had recorded no revenue, compared with €4.5 million a year earlier. It also indicated a cash runway limited to the end of the second quarter of 2027 without additional financing. This outlook was modified by the €103 million Equity offering and the €75 million financing transaction announced on June 2, 2026, whose tranche C could bring in up to €20 million.
Over three months, the stock is still down 14.42%, despite the rebound of recent weeks. In its comments, Jefferies remained at Buy on November 10. A break above resistance at €3.59 is the stock's next technical benchmark.
